Fortrea Holdings (FTRE) Net Income towards Common Stockholders (2022 - 2026)
Fortrea Holdings (FTRE) reported Net Income towards Common Stockholders of -$23.6 million for Q1 2026, down 285.83% quarter-over-quarter from $12.7 million in Q4 2024.
Fortrea Holdings (FTRE) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$23.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders changed N/A year-over-year to -$23.6 million; the trailing twelve-month figure through Mar 2026 stood at -$23.6 million (up 34.08% YoY), and the FY2024 full-year result was -$57.0 million, down 976.92% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$23.6 million, down from $12.7 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $66.4 million in Q2 2022, with the low at -$39.1 million in Q2 2024.
- Historically, Net Income towards Common Stockholders has averaged $3.3 million across 4 years, with a median of -$1.9 million in 2023.
- The largest YoY upside for Net Income towards Common Stockholders was 315.25% in 2024 against a maximum downside of 774.14% in 2024.
- Fortrea Holdings' Net Income towards Common Stockholders stood at -$13.6 million in 2022, then soared by 56.62% to -$5.9 million in 2023, then surged by 315.25% to $12.7 million in 2024, then slumped by 285.83% to -$23.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$23.6 million (Q1 2026), $12.7 million (Q4 2024), and -$9.4 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | -23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2024 | 12.70 Mn |
| Sep 30, 2024 | -9.40 Mn |
| Jun 30, 2024 | -39.10 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Dec 31, 2023 | -5.90 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 5.80 Mn |
| Mar 31, 2023 | 4.50 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | 60.60 Mn |
| Jun 30, 2022 | 66.40 Mn |